* Acutus Medical Inc AFIB.OQ AFIB.O is expected to show
a rise
in quarterly revenue when it reports results on March 30.
* The Carlsbad California-based company is expected to
report a
63.8% increase in revenue to $4.215 million from $2.57 million a
year ago, according to the mean estimate from 6 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Acutus Medical Inc
is for
a loss of 83 cents per share. For the same quarter last year,
the company reported a loss of $1.05 per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Acutus
Medical
Inc is $5, above its last closing price of $1.79.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2021 -0.85 -0.87 -0.94 Missed -8.5
Jun. 30 2021 -0.92 -0.84 -1.02 Missed -21.7
Mar. 31 2021 -0.85 -0.81 -1.04 Missed -28.1
Dec. 31 2020 -0.74 -0.72 -1.05 Missed -45.4
Sep. -1.06 -0.99 -1.95 Missed -96.6
30 2020
Jun. 30 2020 -1.03 -1.03 -32.24 Missed -3,030
.1
This summary was machine generated March 28 at 20:22 GMT. All
figures in US dollars unless otherwise stated